Celia Egan
Internal Medicine · Grand Rapids, MINPI 1831488774
Payments from drug & device makers
Across 143 payments — averaging $377.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$34K
- Novo Nordisk AS$18K
- Echosens North America, Inc.$185
- Astellas Pharma US Inc$170
- Pfizer$136
- Lilly USA, LLC$123
- plus $586 from 17 others
What the payments were for
- Consulting fees$33,93863%
- Travel & lodging$15,98530%
- Food & beverage$3,8347%
- Education$1710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 86 | $34,470 |
| Novo Nordisk AS | 6 | $18,258 |
| Echosens North America, Inc. | 1 | $185 |
| Astellas Pharma US Inc | 5 | $170 |
| Pfizer | 6 | $136 |
| Lilly USA, LLC | 5 | $123 |
| Mayne Pharma Commercial LLC | 8 | $110 |
| Amgen | 5 | $86 |
| Dexcom, Inc. | 2 | $51 |
| Bayer | 3 | $48 |
| Cashflow Solutions, LLC | 2 | $33 |
| Therapeuticsmd, Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| AbbVie | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Abbott | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $18 |
| Vivus LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,927 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 24 | $24,547 |
| Metformin Hcl ErMetformin Hcl | 29 | $441 |
| Topiramate | 14 | $183 |
| Lisinopril | 14 | $103 |
| Lorazepam | 15 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $123 | $24,54724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Grand Rapids
- Leslie PelkeyGrand Rapids$8.5M
- Khan NeddGrand Rapids$2.2M
- Robert SelfeGrand Rapids$238K
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.